Information on medical history, medication use, alcohol use, and current smoking was obtained using standardized self‐report questionnaires. Systolic and diastolic BP measurements were recorded as the mean of 2 readings. Body mass index was calculated as weight in kilograms divided by the square of height in meters, and obesity was defined as body mass index ≥30 kg/m2. Serum glucose was measured using the hexokinase method. Plasma glucose was measured using the hexokinase method. Serum, triglycerides, and high‐density lipoprotein cholesterol concentrations were measured by using automated enzymatic assays. eGFR was calculated from serum creatinine and cystatin C–based new equation.
19 (link) NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was measured using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer (Roche Diagnostics, Mannheim, Germany), and high‐sensitivity cardiac troponin T levels were measured with a highly sensitive assay, Elecsys Troponin T (Roche Diagnostics, Indianapolis, IN) on an automated Cobas e411 analyzer. CRP (C‐reactive protein) was measured via immunophelometric assay.
19 (link) NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was measured using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer (Roche Diagnostics, Mannheim, Germany), and high‐sensitivity cardiac troponin T levels were measured with a highly sensitive assay, Elecsys Troponin T (Roche Diagnostics, Indianapolis, IN) on an automated Cobas e411 analyzer. CRP (C‐reactive protein) was measured via immunophelometric assay.
